DK1026237T3 - Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40 - Google Patents

Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40

Info

Publication number
DK1026237T3
DK1026237T3 DK00104460T DK00104460T DK1026237T3 DK 1026237 T3 DK1026237 T3 DK 1026237T3 DK 00104460 T DK00104460 T DK 00104460T DK 00104460 T DK00104460 T DK 00104460T DK 1026237 T3 DK1026237 T3 DK 1026237T3
Authority
DK
Denmark
Prior art keywords
kinases
tau
inhibitor
protein kinase
neurofilament protein
Prior art date
Application number
DK00104460T
Other languages
Danish (da)
English (en)
Inventor
Vernon M Ingram
Hanno M Roder
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK1026237T3 publication Critical patent/DK1026237T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00104460T 1991-08-09 1992-07-10 Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40 DK1026237T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74288091A 1991-08-09 1991-08-09
EP92915162A EP0667898B1 (de) 1991-08-09 1992-07-10 Verwendungen einer proteinkinase von ton und neurofilament pk40

Publications (1)

Publication Number Publication Date
DK1026237T3 true DK1026237T3 (da) 2004-07-19

Family

ID=24986618

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00104460T DK1026237T3 (da) 1991-08-09 1992-07-10 Anvendelse af en inhibitor af Tau/neurofilament-proteinkinase PK40
DK92915162T DK0667898T3 (da) 1991-08-09 1992-07-10 Anvendelser af TAU/neurofilamentproteinkinasen PK40

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK92915162T DK0667898T3 (da) 1991-08-09 1992-07-10 Anvendelser af TAU/neurofilamentproteinkinasen PK40

Country Status (9)

Country Link
EP (2) EP0667898B1 (de)
JP (1) JPH06510427A (de)
AT (2) ATE262584T1 (de)
AU (1) AU675410B2 (de)
CA (1) CA2115151C (de)
DE (2) DE69232121T2 (de)
DK (2) DK1026237T3 (de)
ES (2) ES2165358T3 (de)
WO (1) WO1993003148A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
JP2004502884A (ja) * 2000-07-07 2004-01-29 ミリケン・アンド・カンパニー 改良された持続性撥水性および汚れ放出性を有する織物基体およびその製造方法
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
JP6358953B2 (ja) * 2011-10-07 2018-07-18 エーシー イミューン エス.エー. タウを認識するホスホ特異的抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506842A (ja) * 1989-09-15 1993-10-07 ジェンシア・ファーマシュウティカルズ・インコーポレイテッド 神経変性状態の処置方法
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
WO1993003177A1 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
EP0544942A1 (de) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neue Werkzeuge für die Diagnose und die Behandlung der Alzheimer-Krankheit

Also Published As

Publication number Publication date
EP1026237A3 (de) 2001-03-28
EP0667898A1 (de) 1995-08-23
DE69233330T2 (de) 2005-03-10
DE69233330D1 (de) 2004-04-29
CA2115151C (en) 2005-05-17
EP1026237B1 (de) 2004-03-24
EP0667898B1 (de) 2001-10-10
ES2165358T3 (es) 2002-03-16
AU675410B2 (en) 1997-02-06
WO1993003148A2 (en) 1993-02-18
AU2324092A (en) 1993-03-02
DE69232121D1 (de) 2001-11-15
WO1993003148A3 (en) 1993-04-01
JPH06510427A (ja) 1994-11-24
CA2115151A1 (en) 1993-02-18
ATE262584T1 (de) 2004-04-15
DK0667898T3 (da) 2002-02-04
ES2216745T3 (es) 2004-11-01
ATE206755T1 (de) 2001-10-15
DE69232121T2 (de) 2002-06-20
EP1026237A2 (de) 2000-08-09

Similar Documents

Publication Publication Date Title
DE69534300D1 (de) Neues multimerisierendes reagenz
EA199700061A1 (ru) Способ получения силденафила
DE68929387D1 (de) Interleukin-1-Inhibitoren
NO944643D0 (no) Protein-kinase-C-hemmere
IE892272L (en) Novel fused heterocyclic compounds
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
DE69412828D1 (de) Zusammensetzung zur benetzung von kontaktlinsen
ATE236886T1 (de) 2,4-dioxo-imidazolidin-derivate
AU2178895A (en) Heterocyclic-cyclic amine derivatives
DK0788356T3 (da) Fremgangsmåde og præparater til hæmning af proteinkinaser
DK0619806T3 (da) Fremstilling af substituerede piperidiner
DE59507591D1 (de) Stabile kristalline (6S)- und (6R)-Tetrahydrofolsäure
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
DK0667898T3 (da) Anvendelser af TAU/neurofilamentproteinkinasen PK40
DK0589949T3 (da) Hidtil ukendte peptider, fremgangsmåder til fremstilling heraf og anvendelse af disse
DE59900730D1 (de) Korrosionsinhibitoren enthaltender Injektionszement
DK0640608T3 (da) Mellemprodukter til syntese af cephalosporiner
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
DK192890A (da) 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
DK0689440T3 (da) Anvendelse af triazinforbindelser som anxiolytikum
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
DK509085D0 (da) Fremgangsmaade til stabilisering af bacampicillinhydroklorid
FI920926A7 (fi) Menetelmä korkea-alkalisten proteaasien stabiilisuuden parantamiseksi